Medisense Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$51,812	33
2024	Research	$17,407	11
2023	Research	$81,173	28
2022	Research	$172,259	44
2021	Research	$155,934	24
2020	Research	$403,481	62
2019	Research	$471,875	111

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $1,108,186 213 payments
Sumitomo Pharma America, Inc. $103,087 58 payments
Myovant Sciences GmbH $93,667 34 payments
Bayer HealthCare Pharmaceuticals Inc. $41,877 5 payments
Mylan Inc. $5,641 1 payment
Myovant Sciences Inc. $1,399 1 payment
Mylan Technologies Inc. $84 1 payment

Studies the money was for Research payments · program years 2019–2025

M16-283 $733,395 167 payments
M16-824 $141,961 6 payments
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $85,564 34 payments
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $77,734 11 payments
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $54,194 7 payments
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $51,812 33 payments
Assess efficacyand safetyof three different doses of P2X3 antagonist in women with symptomatic endometriosis $41,877 5 payments
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $40,719 10 payments
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $34,924 7 payments
Serene $20,964 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.